Unternehmensübersicht
Immatics N.V. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of potential T cell redirecting immunotherapies designed for the treatment of cancer within the United States market. The company functions specifically within the healthcare sector and the biotechnology industry, focusing on creating targeted immunotherapies with a strategic emphasis on treating solid tumors. As of the latest available data, Immatics N.V. holds a market capitalization of $1.26B while reporting annual revenue of $48.27M and maintaining an organizational scale of 589 employees. The combination of a market cap exceeding $1 billion and a revenue base of approximately $48 million indicates that the company has achieved a significant valuation tier typical for established biotechnology firms, yet the revenue figure relative to the market cap suggests the market is pricing in substantial future growth potential rather than current cash flow generation.
Finanzielle Gesundheit
The company reported a revenue of $48.27M over the trailing twelve months, yet this revenue generated a net income of $-196,447,008, revealing a cost structure where expenses significantly outweigh income to the extent that the profit margin stands at 0.0%. The EBITDA for the same period was $-172,875,008, indicating that even before interest and taxes, the operational activities resulted in a substantial deficit. Free cash flow stood at $-128,190,248, which implies that the company is currently burning cash rather than generating liquidity from its core operations. This negative free cash flow necessitates ongoing capital raising or the utilization of existing reserves to fund research and development activities. Regarding profitability metrics, the gross margin is reported at -280.9%, the operating margin at -196.8%, and the profit margin at 0.0%, all of which reflect the high-burn nature of the clinical-stage development phase where revenue does not yet cover the costs of goods sold or operations. On the balance sheet side, the company holds $469.34M in cash against $15.63M in debt, resulting in a debt-to-equity ratio of 3.23, which presents a complex picture of high leverage relative to equity but substantial liquidity coverage. The current ratio of 11.72 indicates an exceptionally strong short-term liquidity position, suggesting the company has more than sufficient current assets to cover its short-term liabilities despite the negative earnings. Finally, the return on equity is -37.1% and the return on assets is -18.1%, metrics that reveal that management effectiveness in generating shareholder value is currently negative due to the aggressive investment strategy required for clinical-stage drug development.
Bewertungsanalyse
Valuation multiples for Immatics N.V. show a trailing P/E ratio of N/A due to the lack of positive net income, while the forward P/E is listed at -5.31, implying that the market expects earnings to improve or that the current valuation model relies heavily on future cash flow assumptions rather than historical profitability. The price-to-book ratio is 2.25, indicating that the market values the company at a premium of roughly 125% above its book value, reflecting the perceived value of its intangible assets and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 26.03 and the EV/EBITDA of -4.64 suggest that the market is pricing the stock based on revenue multiples and enterprise value relative to earnings power, typical for biotech assets with limited historical profitability. The stock's price range over the last 52 weeks has fluctuated between a high of $12.41 and a low of $3.30, meaning the current price sits within a volatile band that reflects high uncertainty surrounding the company's clinical milestones. The beta value of 1.35 indicates that the stock price exhibits volatility that is 35% higher than the broader market, highlighting the heightened risk profile associated with small-cap biotechnology equities.
Growth & Income
The company experienced a revenue growth of -64.9% year-over-year, while earnings growth is listed as N/A, indicating that earnings are not growing in the traditional sense due to the absence of profitability rather than a divergence between revenue and earnings rates. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Since the company is not a dividend payer, it effectively reinvests all available earnings or cash reserves back into its research and development operations to fund the progression of its immunotherapy candidates. The overall growth and income profile is characterized by significant recent revenue contraction and a complete absence of dividend income, typical for a clinical-stage biopharmaceutical company prioritizing capital expenditure over shareholder returns.